Gangstörungen im Alter: Perspektiven der symptomatischen Therapie

K. Jahn

doi:10.1055/s-0031-1299428

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr 2012; 80(5): 260-266
DOI: 10.1055/s-0031-1299428

Übersicht

Gangstörungen im Alter: Perspektiven der symptomatischen Therapie

Gait Disorders in the Elderly: Prospects for a Symptomatic Therapy

Authors

K. Jahn

Abstract

Zusammenfassung

Gangstörungen gehören zu den häufigsten Leitsymptomen in der Neurologie. Im Alter kommen oft mehrere Faktoren als Ursache von Gangunsicherheit und chronischem Schwindel zusammen. Relevante pathogenetische Faktoren sind sensorische Defizite (visuell, vestibulär, somatosensorisch), neurodegenerative Prozesse (kortikal, extrapyramidal-motorisch, zerebellär), toxische Einflüsse (Medikamente, Alkohol) und Angst (primär oder als Folge von Stürzen). Die Einschränkung der Mobilität führt zu einer erheblichen Minderung der Lebensqualität; assoziierte Stürze erhöhen Morbidität und Mortalität. Die Untersuchung betagter Patienten mit dem Leitsymptom „Gangstörung“ sollte die Identifizierung der spezifischen Defizite zum Ziel haben. So kann auch bei multifaktorieller Genese eine gezielte Therapie erfolgen. Neben der Behandlung der Grunderkrankung besteht der Bedarf für wirksame symptomatische Therapieoptionen, insbesondere bei degenerativen Erkrankungen. Krankengymnastisch unterstütztes Stand- und Gangtraining ist ein wesentlicher Bestandteil der Behandlung und kann die Gangsicherheit verbessern und Stürze verhindern. Die symptomatische medikamentöse Therapie ist unbefriedigend. Pathogenetisch sinnvolle Therapieansätze mit ermutigenden Resultaten in unkontrollierten Studien sind die Verstärkung der cholinergen Neurotransmission in Mittelhirn und Thalamus mit zentral wirksamen Cholinesterasehemmern und die Regularisierung der Purkinjezellfunktion im Kleinhirn mit Kaliumkanalblockern. Kerngebiete im Hirnstamm, die Zielregionen der tiefen Hirnstimulation sind (N. subthalamicus, N. pedunculopontinus), entsprechen wichtigen Zentren für die Gangsteuerung (subthalamisches und mesencephales Lokomotionszentrum). Entsprechend beeinflusst die Therapie die Stand- und Gangfähigkeit. Die aktuelle Studienlage zur symptomatischen Therapie von Gangstörungen im Alter wird zusammengefasst.

Abstract

Gait disorders are among the most common presenting symptoms in neurology. In the elderly, multiple causes of gait instability and dizziness may occur in the same subject. Relevant pathogenetic factors are sensory deficits (visual, vestibular, somatosensory), neurodegenerative processes (cortical, extrapyramidal, cerebellar), toxic factors (medication, alcohol) and anxiety (primary or as the result of falls). Reduced mobility reduces the quality of life; associated falls increase morbidity and mortality. The evaluation of aged people with the chief complaint “gait disorder” should focus on the identification of specific deficits. This is the prerequisite for reasoned therapy. Besides treatment of the underlying pathology there is a need for effective symptomatic therapy, in particular for degenerative disorders. Physical therapy with postural and locomotor training remains the basis of treatment; it can improve gait and prevent falls. So far, symptomatic drug treatment is unsatisfactory. Based on pathophysiology and uncontrolled studies, the most promising approaches are to support cholinergic neurotransmission in the midbrain and thalamus by central cholinesterase inhibitors and the regularisation of Purkinje cell function by potassium channel blockers. Brain stem nuclei which are target regions for deep brain stimulation (subthalamic and pedunculopontine nucleus) are known to be relevant for locomotor control (subthalamic and mesencephalic locomotor region). Accordingly, deep brain stimulation also affects posture and gait. The current literature on symptomatic therapy for gait disorders in the elderly is summarised.

Schlüsselwörter

Alter - Gangstörung - Lokomotion - Stürze

Key words

age - gait disorder - locomotion - falls

Volltext

Referenzen

Literatur
1 Stolze H, Klebe S, Baecker C et al. Prevalence of gait disorders in hospitalized neurological patients. Mov Disord 2005; 20: 89-94
2 Verghese J, Levalley A, Hall CB et al. Epidemiology of gait disorders in community-residing older adults. J Am Geriatr Soc 2006; 54: 255-261
3 Sudarsky L. Gait disorders: prevalence, morbidity, and etiology. Adv Neurol 2001; 87: 111-117
4 Stolze H, Klebe S, Zechlin C et al. Falls in frequent neurological diseases – prevalence, risk factors and aetiology. J Neurol 2004; 251: 79-84
5 Alexander NB. Definition and epidemiology of falls and gait disorders. In: Sirven JI, Malamut BL, (Hrsg) Clinical neurology of the older adult. Philadelphia: Lippincott Williams & Wilkins; 2002: 108-116
6 Jorstad EC, Hauer K, Becker C et al. Measuring the psychological outcomes of falling: a systematic review. J Am Geriatr Soc 2005; 53: 501-510
7 Hough JC, McHenry MP, Kammer LM. Gait disorders in the elderly. Am Fam Physician 1987; 35: 191-196
8 Grillner S. Control of locomotion in bipeds, tetrapods and fish. In: Brooks VB, (Hrsg) Handbook of Physiology, The Nervous System, Vol. II, Motor control, Part 2. Bethesda, MD: American Physiological Society; 1981: 1179-1236
9 Dietz V. Spinal cord pattern generators for locomotion. Clin Neurophysiol 2003; 114: 1379-1389
10 Dietz V, Colombo G, Jensen L. Locomotor activity in spinal man. Lancet 1994; 344: 1260-1263
11 Dietz V. Do human bipeds use quadrupedal coordination?. Trends Neurosci 2002; 25: 462-467
12 Jahn K, Deutschländer A, Stephan T et al. Brain activation patterns during imagined stance and locomotion in functional magnetic resonance imaging. Neuroimage 2004; 22: 1722-1731
13 Jahn K, Deutschländer A, Stephan T et al. Supraspinal locomotor control in quadrupeds and humans. Prog Brain Res 2008; 171: 353-362
14 Ashton-Miller JA. Age-associated changes in the biomechanics of gait and gait-related falls in older adults. In: Hausdorff JM, Alexander NB, (Hrsg) Gait disorders: evaluation and management. Boca Raton: Taylor & Francis; 2005: 63-100
15 Jahn K, Zwergal A, Schniepp R. Gait disturbances in old age: classification, diagnosis, and treatment from a neurological perspective. Dtsch Arztebl Int 2010; 107: 306-315
16 Stolze H, Vieregge P, Deuschl G. Gait disturbances in neurology. Nervenarzt 2008; 79: 485-499
17 Zwergal A, Linn J, Xiong G et al. Aging of human supraspinal locomotor and postural control in fMRI. Neurobiol Aging 2011; in press
18 Snijders AH, van de Warrenburg BP, Giladi N et al. Neurological gait disorders in elderly people: clinical approach and classification. Lancet Neurol 2007; 6: 63-74
19 Lundin-Olsson L, Nyberg L, Gustafson Y. “Stops walking when talking” as a predictor of falls in elderly people. Lancet 1997; 349: 617
20 Verghese J, Kuslansky G, Holtzer R et al. Walking while talking: effect of task prioritization in the elderly. Arch Phys Med Rehabil 2007; 88: 50-53
21 Hausdorff JM, Schweiger A, Herman T et al. Dual-task decrements in gait: contributing factors among healthy older adults. J Gerontol A Biol Sci Med Sci 2008; 63: 1335-1343
22 Podsiadlo D, Richardson S. The Timed “Up&Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142-148
23 Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 1986; 34: 119-126
24 Yardley L, Beyer N, Hauer K et al. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing 2005; 34: 614-619
25 Delbaere K, Close JC, Mikolaizak AS et al. The Falls Efficacy Scale International (FES-I). A comprehensive longitudinal validation study. Age Ageing 2010; 39: 210-216
26 Tinetti ME. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 1990; 112: 699-706
27 Rubenstein LZ, Robbins AS. Falling syndromes in elderly persons. Compr Ther 1989; 15: 13-18
28 Robbins AS, Rubenstein LZ, Josephson KR et al. Predictors of falls among elderly people. Results of two population-based studies. Arch Intern Med 1989; 149: 1628-1633
29 Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-773
30 Nevitt MC, Cummings SR, Kidd S et al. Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA 1989; 261: 2663-2668
31 Nguyen T, Sambrook P, Kelly P et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993; 307: 1111-1115
32 Morris ME. Locomotor training in people with Parkinson disease. Phys Ther 2006; 86: 1426-1435
33 Auriel E, Hausdorff JM, Herman T et al. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin Neuropharmacol 2006; 29: 15-17
34 Pollak L, Dobronevsky Y, Prohorov T et al. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neural Transm Suppl 2007; 145-148
35 Devos D, Krystkowiak P, Clement F et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 470-475
36 Ben-Itzhak R, Giladi N, Gruendlinger L et al. Can methylphenidate reduce fall risk in community-living older adults? A double-blind, single-dose cross-over study. J Am Geriatr Soc 2008; 56: 695-700
37 Nutt JG, Bloem BR, Giladi N et al. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol 2011; 10: 734-744
38 Espay AJ, Dwivedi AK, Payne M et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011; 76: 1256-1262
39 Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518
40 Yener GG, Kaya GC, Ozturk V et al. Improvement in Tc-99m HMPAO brain SPECT findings during donepezil therapy in a patient with pure akinesia. Ann Nucl Med 2005; 19: 607-609
41 Chung KA, Lobb BM, Nutt JG et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75: 1263-1269
42 Jahn K, Deutschländer A, Stephan T et al. Imaging human supraspinal locomotor centers in brainstem and cerebellum. Neuroimage 2008; 39: 786-792
43 Bohnen NI, Frey KA. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 2007; 9: 243-257
44 Zwergal A, la Fougère C, Lorenzl S et al. Postural imbalance and falls in PSP correlate with functional pathology of the thalamus. Neurology 2011; 77: 101-119
45 Ferraye MU, Debû B, Fraix V et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain 2010; 133: 205-214
46 Ferraye MU, Debû B, Fraix V et al. Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease. Neurology 2008; 70: 1431-1437
47 Alam M, Schwabe K, Krauss JK. The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation. Brain 2011; 134: 11-23
48 Thevathasan W, Coyne TJ, Hyam JA et al. Pedunculopontine nucleus stimulation improves gait freezing in Parkinson disease. Neurosurgery 2011; 69: 1248-1253
49 Giladi N. Medical treatment of freezing of gait. Mov Disord 2008; 23 (Suppl. 02) S482-S488
50 Chung KA, Carlson NE, Nutt JG. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 2005; 64: 1797-1798
51 Giladi N, McDermott MP, Fahn S et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56: 1712-1721
52 Strupp M, Schuler O, Krafczyk S et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 2003; 61: 165-170
53 Kalla R, Glasauer S, Buttner U et al. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 2007; 130: 2441-2451
54 Strupp M, Kalla R, Dichgans M et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004; 62: 1623-1625
55 Strupp M, Kalla R, Claassen J et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011; 77: 269-275
56 Schniepp R, Wuehr M, Ackl N et al. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J Neurol 2011; 258: 1708-1711
57 Otis TS, Jen JC. Blessed are the pacemakers. Nat Neurosci 2006; 9: 297-298
58 Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738
59 Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502
60 Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993; 43: 268-79
61 Jahn K, Zwergal A. Functional imaging of locomotion and navigation – physiology and neurodegeneration. Nervenarzt 2010; 81: 1450-1455